跳至主要内容
临床试验/KCT0002168
KCT0002168尚未招募未知

Electro-acupuncture for cancer-related cognitive impairment: a single group, before-after, feasibility study

Korea Institute of Oriental Medicine0 个研究点目标入组 15 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 74(Year)(—)
性别
All

入选标准

  • 1. Aged equal to or more than 19 to under 75 years
  • 2. solid cancer occured in adult age, 6 months after finishing cancer treatment (hormone therapy is allowed)
  • 3. Complaint of cognitive impairment with The functional assessment of cancer therapy-cognitive function-perceived cognitive impairments (FACT-cog-PCI score) <63
  • 4. Cognitive impairment is suppose to be accompanied with cancer treatment
  • 5. Eastern cooperative oncology group (ECOG) performance status 0~2
  • 6. agreed with written informed consent

排除标准

  • 1. currently receiving any of cognitive rehabilitation therapy, herbal medicine or conventional treatment for cognitive impairment; or having experiences of those treatment within 2 weeks
  • 2. history of tumor in central nervous system (CNS), intra-cranial radiotherapy, or intrathecal chemotherapy; or history of CNS diseases which can affect cognitive function
  • 3. Recurrence, metastasis or progression of cancer
  • 4. history of psycological disorders including alcohol dependence, major depressive disorder, schizophrenia or bipolar disorder
  • 5. Korean Vision of Mini-Mental State Exam (K-MMSE) score <20
  • 6. score of any field of Hospital anxiety and depression scale (HADS) is equal to or greater than 11
  • 7. One or more of belows: Platelet count = 60,000/µL, Hemoglobin < 8g/dL, or absolute neutrophil count < 1,000
  • 8. abnormal values of liver function test (LFT) or renal function test (RFT), serious hepatic/renal failure (equal to or more than two times of upper limit of AST or ALT or creatinine = 2.0mg/dL )
  • 9. suspected clinically significant inflammation with CRP = 10mg/L and WBC > 10,000/µL
  • 10. serum albumin value under normal range and poor oral intake
  • 11. seriously unstable medical condition such as abnormal condition demanding medical intervention or management
  • 12. life expectancy = 6 months
  • 13. planning operation, chemotherapy or radiotherapy during the clinical trial period
  • 14. receiving active treatment for anemia (erythropoietin or blood transfusion)
  • 15. history of hypersensitivity reaction to acupuncture or electroacupuncture; or difficult to cooperate for the intervention
  • 16. inserted prosthesis which is inappropriate for electroacupuncture (pace maker, a heart-lung machine, an electroacrdiograph etc.), or who has possibility of hypersensitivity reaction to electroacupuncture including epilepsy
  • 17. currently being enrolled on another clinical trial or it is not passed 4 weeks after completion of previous clinical trial
  • 18. pregnant women, lactating women, or planning for pregnancy
  • 19. difficult to comply the treatment, visit or reponse to questionnaires etc.

研究者

相似试验